BALA CYNWYD, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation to you. BioDelivery Sciences International, Inc. (Nasdaq - BDSI) Under the terms of the agreement, BDSI will be acquired by Collegium Pharmaceutical, Inc. (Nasdaq - COLL). BDSI shareholders will receive $5.60 in cash for each share of BDSI common stock that they hold. The transaction is valued at approximately $604 million. The investigation concerns whether the BDSI Board breached its fiduciary duties to ...Full story available on Benzinga.com
BDSI is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies for the treatment of debilitating chronic conditions.